Business, energy, technology, markets and global industry news from Business News Today

cabozantinib

PharmaDeviceNews cabozantinib
Representative image of oncology researchers studying tumor biology in a modern laboratory, reflecting Exelixis’ CABINET trial data on CABOMETYX and its potential role in advanced neuroendocrine tumor treatment.
Pharma & Biotech

Can Exelixis defend its oncology franchise with deeper CABINET evidence?

Read how Exelixis’ CABINET subgroup data could sharpen cabozantinib’s role in advanced neuroendocrine tumor care.

Read More
Pharma & Biotech

What Kura Oncology’s latest data reveals about resistance biology in kidney cancer

Can darlifarnib overcome VEGF resistance in kidney cancer? Explore what Kura Oncology’s latest data could mean for future treatment strategies.

Read More